Skip to search formSkip to main contentSkip to account menu

mocetinostat

Known as: Benzamide, N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]-, N-(2-aminophenyl)-4-((4-pyridin-3-ylpyrimidin-2-ylamino)methyl)benzamide 
A rationally designed, orally available, Class 1-selective, small molecule, 2-aminobenzamide HDAC inhibitor with potential antineoplastic activity… 
National Institutes of Health

Related topics

Related topics

10 relations
Angiogenesis InhibitionHistone DeacetylaseMocetinostat DihydrobromideNCIt Antineoplastic Agent Terminology

Broader (3)

BenzamidesHistone deacetylase inhibitorPyrimidines

Narrower (1)

MGCD 0103

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Preclinical and clinical studies of a class I/IV HDAC inhibitor, mocetinostat, in melanoma.
10052Background: Mocetinostat is a class I/IV HDAC inhibitor with HDAC1/2/3/11 activity. Preclinical murine data suggest that… 
Highly Cited
2017
Highly Cited
2017
Corrigendum: Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma
Scientific Reports 7: Article number: 44079; published online: 09 March 2017; updated: 21 April 2017. In this Article, Monika… 
Review
2015
Review
2015
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases
Neurodegenerative diseases (NDs) are among the most feared of the disorders that afflict humankind for the lack of specific… 
2015
2015
Metabolic changes in rats after intragastric administration of MGCD0103 (Mocetinostat), a HDAC class I inhibitor.
MGCD0103, an isotype-selective HDACi, has been clinically evaluated for the treatment of hematologic malignancies and advanced… 
2014
2014
Liquid chromatography mass spectrometry determination of mocetinostat (MGCD0103) in rat plasma and its application to a pharmacokinetic study
Abstract 1. Mocetinostat (MGCD0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of… 
Review
2014
Review
2014
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
Hodgkin lymphoma (HL) relapsing after an autologous hematopoietic cell transplant (HCT) poses a therapeutic challenge. In this… 
2013
2013
A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS).
7116 Background: Mocetinostat (MGCD0103) is an orally available, isotype-selective, non-hydroxamate HDAC inhibitor targeting… 
2013
2013
A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.
8535 Background: Mocetinostat (MGCD0103) is an orally available, isotype-selective, non-hydroxamate HDAC inhibitor targeting… 
Review
2012
Review
2012
Novel Agents in Hodgkin Lymphoma
Despite the success of modern therapy for Hodgkin lymphoma (HL), about 15 % of patients will fail both first-line and second-line… 
2010
2010
The Histone Deacetylase Inhibitor MGCD0103 Has Both Deacetylase and Microtubule Inhibitory Activity
Histone deacetylase inhibitors (HDACis) are currently in trial or are in clinical use for the treatment of a number of tumor… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)